Evidence map›Paper›PMID 34917553›Full record

ArticleJournal of hepatocellular carcinoma2021

Experimental Validation of Novel Glypican 3 Exosomes for the Detection of Hepatocellular Carcinoma in Liver Cirrhosis.

Yucel Aydin, Ali Riza Koksal, Paul Thevenot, Srinivas Chava, Zahra Heidari, Dong Lin, Tyler Sandow, Krzysztof Moroz, Mansour A Parsi, John Scott and 2 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatocellular carcinoma, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Yucel AydinDepartment of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA.
Ali Riza KoksalDepartment of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA.
Paul ThevenotInstitute of Translational Research, Ochsner Health, New Orleans, LA, USA.
Srinivas ChavaDepartment of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA.
Zahra HeidariChemical and Biomedical Engineering, Tulane University, New Orleans, LA, USA.
Dong LinDepartment of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA.
Tyler SandowDepartment of Radiology, Institute of Translational Research, Ochsner Health, New Orleans, LA, USA.
Krzysztof MorozDepartment of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA.
Mansour A ParsiDepartment of Gastroenterology and Hepatology, Tulane University Health Sciences Center, New Orleans, LA, USA.
John ScottDepartment of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA.
Ari CohenInstitute of Translational Research, Ochsner Health, New Orleans, LA, USA.
Srikanta DashDepartment of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA.
Tulane University · USOchsner Health System · USSoutheast Louisiana Veterans Health Care System · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
BLRD VA I01 BX004516NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

BACKGROUND AND

aimsHepatocellular carcinoma (HCC) developing in the context of preexisting cirrhosis is characterized by impaired autophagy that results in increased exosome release. This study was conducted to determine whether circulating exosomes expressing glypican 3 (GPC3) could be utilized as a biomarker for HCC detection and treatment response in patients with cirrhosis.

methodsImmunohistochemistry was performed to assess p62 and GPC3 expression in the lesion and adjacent tissue from cirrhosis with HCC. GPC3-enriched exosomes were captured by an enzyme-linked immunosorbent assay (ELISA). The diagnostic specificity of serum exosome-derived GPC3 (eGPC3) was determined using samples obtained from malignancy-free controls, malignancy-free cirrhotics, cirrhotics with confirmed HCC, and patients with a non-HCC malignancy. The performance of eGPC3 was validated using serum samples of HCC patients received chemotherapy.

resultsWe found that the expression of p62 and GPC3 was significantly increased in HCC tissues compared to adjacent cirrhotic liver. Impaired autophagy and exosome shedding were confirmed in HCC cell lines. Mass spectroscopic analysis revealed that GPC3 was enriched in exosomes isolated from HCC cell lines. An affinity ELISA assay was developed that specifically captures GPC3 positive exosomes in the serum. Total exosome concentration and eGPC3 were significantly elevated in cirrhotic patients with HCC as compared to the reference control groups. Furthermore, decreases in post-treatment exosome concentration and eGPC3 levels were more closely correlated with response to locoregional chemotherapy compared to change in serum AFP in HCC patients awaiting liver transplantation.

conclusionWe developed an affinity exosome capture assay to detect GPC3 enriched exosomes. Our preliminary assessment shows that GPC3 positive exosomes can be used for HCC detection and prediction of treatment outcomes.

Indexed as

autophagyexosomeglypican 3hepatocellular carcinomasurveillance

Identifiers

PMID34917553
PMCPMC8671108
OpenAlexW4200520158

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.